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A B S T R A C T
Background: Understanding the age at which persistent socioeconomic inequalities in cancer survival
become apparent may help motivate and support targeting of cancer site-speciﬁc interventions, and
tailoring guidelines to patients at higher risk.
Patients and methods: We analysed data on more than 40,000 patients diagnosed in England with one of
three common cancers in men and women, breast, colon and lung, 2001–2005 with follow-up to the end
of 2011. We estimated net survival for each of the ﬁve deprivation categories (afﬂuent, 2, 3, 4, deprived),
cancer site, sex and age group (15–44, 45–54, 55–64, and 65–74 and 75–99 years).
Results: The magnitude and pattern of the age speciﬁc socioeconomic inequalities in survival was
different for breast, colon and lung. For breast cancer the deprivation gap in 1-year survival widened
with increasing age at diagnosis, whereas the opposite was true for lung cancer, with colon cancer having
an intermediate pattern. The ‘deprivation gap’ in 1-year breast cancer survival widened steadily from
0.8% for women diagnosed at 15–44 years to 4.8% for women diagnosed at 75–99 years, and was the
widest for women diagnosed at 6574 years for 5- and 10-year survival. For colon cancer in men, the gap
was widest in patients diagnosed aged 55–64 for 1-, 5- and 10-year survival. For lung cancer, the
‘deprivation gap’ in survival in patients diagnoses aged 15–44 years was more than 10% for 1-year
survival in men and for 1- and 5-year survival in women.
Conclusion: Our ﬁndings suggest that reduction of socioeconomic inequalities in survival will require
updating of current guidelines to ensure the availability of optimal treatment and appropriate
management of lung cancer patients in all age groups and older patients in deprived groups with breast
or colon cancer.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
Cancer Epidemiology
The International Journal of Cancer Epidemiology, Detection, and Prevention
jou r nal h o mep age: w ww.c an cer ep idem io log y.n et1. Introduction
In spite of notable improvements in cancer survival in recent
decades, socioeconomic inequalities in survival persist for the
great majority of common cancers in adults [1–3]. For many
cancers, however, survival has improved more rapidly for patients
living in more afﬂuent areas than for those living in deprived areas
[4], including cancers of the breast, colon and lung [5–7]. These
trends have led to wider socioeconomic inequalities (‘deprivation
gap’) in survival in the last two decades, in spite of major policy
initiatives designed to improve outcomes and reduce inequality
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4.0/).A different picture is apparent for childhood cancers. The
survival of children with cancer has improved more rapidly than
that of adult patients in recent decades, chieﬂy reﬂecting notable
advances in chemotherapy for many childhood cancers [9–11]. In
addition, socioeconomic inequalities have not been observed for
childhood cancers [12]. This may reﬂect a range of factors
including the availability of effective treatments for many
childhood cancers, the centralisation of care in specialist hospitals,
and the high proportion of children treated in clinical trials [12].
These observations pose a question about the age-speciﬁc
socioeconomic inequalities in cancer survival. Understanding this
may help motivate and support targeting of interventions and
tailoring guidelines to patients at higher risk. The answer to this
question may also provide insights into the mechanisms respon-
sible for socioeconomic inequalities in cancer survival and the
potential contribution of differences in diagnosis. Against thise under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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inequalities in survival for three common cancers in several age
groups.
2. Patients and methods
All adults aged 15–99 years diagnosed in England with a ﬁrst,
invasive, primary malignant neoplasm of the breast (International
Classiﬁcation of Diseases, tenth revision [13] (ICD-10), C50), colon
(C18) or lung (C33, C34) during the 5 years from 2001 to 2005, with
follow-up to 31 December 2011 were considered for analysis.
These three cancer sites are characterised by high incidence
(allowing for more precise survival estimates by age and
deprivation group), variable prognosis and a persistent ‘depriva-
tion gap’ in survival in recent periods [1,3].
Standard exclusion criteria were used to decide whether a
patient record was eligible for inclusion [1,14]. Cases were
excluded if the cancer was only registered from the death
certiﬁcate (DCO) (14,853 (3.5%)), or for unknown vital status or
sex, duplicate registration, synchronous tumours, or invalid dates
or sequences of dates (10,178 (2.4%)). Patients who had had a
previous cancer of the same organ at any time since 1971 were also
excluded (Table 1). One day was added to the survival time of
patients for whom the dates of diagnosis and death were the same
(zero survival), enabling the inclusion of these patients in analyses.
Age at diagnosis was categorised in ﬁve groups (15–44, 45–54, 55–
64, 65–74, and 75–99 years).
The Ofﬁce for National Statistics (ONS) provides information on
each patient’s vital status (alive, dead, emigrated or lost to follow-
up) and their postcode of residence at diagnosis, from which
patients were assigned to one of ﬁve deprivation categories (from
most afﬂuent (1) to most deprived (5)). An ecological deprivation
score was assigned to each patient based on the characteristics of
the Lower Super-Output Area (LSOA) in which the patient was
resident at the time of diagnosis, and the year of diagnosis. The
LSOAs in England are small areas (mean population 1500), covering
the whole of England and for which detailed data on housing,
income and employment are available. These information can be
used to characterise the level of the socioeconomic group of
residents. These groups were deﬁned by quintiles of the income
domain score of the Indices of Multiple Deprivation (IMD) [15] of
34,378 LSOAs in England.
Net survival is the survival probability we would observe if the
disease under study was the only cause of death. It may be
interpreted as the survival of cancer patients after controlling for
competing causes of death. This method is recommended for the
estimation of cancer survival when the cause of death is either
unknown or unreliable. It estimates the excess mortality due to
cancer as the difference between the all-cause mortality experi-
enced by cancer patients and the expected or ‘background’
mortality derived from life tables of all-cause death rates of the
general population. We used cancer registry data to estimate all-
cause mortality, and life tables to estimate the expected orTable 1
Number of patients eligible for analysis, exclusions, and number (%) of eligible patients 
2005 and followed up to 2011.
Malignancy ICD-10 Eligible 
codea
Colon C18 90,928 
Lung C33, C34 155,555 
Breast (women) C50 183,885 
a International Classiﬁcations of Diseases, tenth edition.
b Registration from a death certiﬁcate only (DCO): date of diagnosis unknown.
c Aged 100 years or over at diagnosis, sex or vital status unknown, sex-site error, inva
1971.background mortality in the general population. Background
mortality varied between socioeconomic groups and geographic
regions in England. Death records were assigned to deprivation
categories using the postcode and LSOA. Abridged (5-year) life
tables were completed and extended to age 99 years and smoothed
using ﬂexible parametric Poisson regression with spline functions
to model the death rate. We then derived complete (single-year-of-
age) life tables by sex, socioeconomic group, geographic region and
calendar year for 2001–2009 (Cancer Research UK Cancer Survival
Group, 2004). Life tables for 2010–2011 could not be constructed
because the relevant data (death during 2010–2011) were
unavailable, so life tables for 2009 were used for these years.
We estimated net survival every six months and up to 10 years
after diagnosis for each of the ﬁve deprivation categories, cancer
site, sex and each of the ﬁve age groups using the Pohar Perme
estimator [16].
The ‘deprivation’ gap was quantiﬁed as the ﬁtted difference
between survival in the ‘most afﬂuent’ and the ‘most deprived’,
using weighted least-squares regression [17] for each cancer site,
sex and age group. A negative gap indicates that net survival was
lower in the most deprived group than the most afﬂuent group.
This gap was quantiﬁed for each year up to 10 years after diagnosis.
All analyses were carried out in Stata 13 [18], including net
survival analyses with stns [19].
3. Results
A total of 405,796 patients diagnosed between 2001 and
2005 and followed up to 2011 were included in the analyses
(Table 1). The three cancer sites are more commonly diagnosed at
an older age, with very few patients diagnosed with lung and
colon in the youngest age group 15–55 (Table 2). While breast and
colon cancer are more common among afﬂuent patients, the
percentage of lung cancer patients diagnosed late in life (75–99)
are almost double those in the afﬂuent group (Table 2). Table 3
summarises the 1-, 5, and 10-year survival for each cancer.
Patterns of the ‘deprivation gap’ up to 5 years by age group are
presented in Fig. 1. Net survival up to 10 years after diagnosis for
the most afﬂuent and the most deprived groups in the three age
groups 15–44, 55–64 and 75–99 years, for each of the three
cancers and sex in England are presented in Fig. 2. Net survival
could not be estimated for colon cancer in men in the deprived
youngest age group 14–55, due to the small number of patients.
The detailed estimates of 1-, 5- and 10-year net survival are
presented in Appendices A–C.
The age-speciﬁc patterns of socioeconomic inequalities in
survival differed between the three cancers. For breast cancer, the
socioeconomic deprivation gap in 1-year survival widened with
increasing age at diagnosis, whereas the opposite was true for
lung cancer, with colon cancer having an intermediate pattern
(Fig. 1, Table 3).
One-year survival for women with breast cancer for all ages
and deprivation groups combined was high (97%). It was similarincluded in analyses: three cancers, England, adults(15–99 years) diagnosed 2001–
Exclusions Included
DCOb Otherc Number %
3,129 1,880 86,378 95.0
8,991 1,032 145,532 93.6
2,733 7,266 173,886 94.6
lid dates, missing deprivation category, or previous cancer of the same organ since
Table 2
Distribution of patients eligible for survival analysis, by age group, deprivation category and sex: adults (15–99 years) diagnosed 2001–2005 and followed up to 2011 in
England.
Age group Deprivation Breast Colon Lung
Women Men Women Men Women
N % N % N % N % N %
15–44 Afﬂuent 4,503 2.6 230 0.5 239 0.6 125 0.1 132 0.2
2 4,189 2.4 196 0.4 201 0.5 128 0.1 154 0.3
3 3,877 2.2 195 0.4 215 0.5 197 0.2 173 0.3
4 3,950 2.3 223 0.5 223 0.5 227 0.3 203 0.3
Deprived 3,421 2.0 252 0.6 212 0.5 309 0.4 262 0.4
45–54 Afﬂuent 8,594 4.9 543 1.2 561 1.3 583 0.7 534 0.9
2 7,867 4.5 538 1.2 505 1.2 761 0.9 657 1.1
3 7,301 4.2 529 1.2 510 1.2 859 1.0 729 1.2
4 6,553 3.8 506 1.1 440 1.0 1,125 1.3 967 1.6
Deprived 5,273 3.0 457 1.0 421 1.0 1,514 1.8 1,175 2.0
55–64 Afﬂuent 10,410 6.0 1,772 4.0 1,331 3.1 2,196 2.5 1,342 2.3
2 10,102 5.8 1,650 3.7 1,344 3.2 2,621 3.0 1,680 2.8
3 9,147 5.3 1,526 3.5 1,256 3.0 3,165 3.7 2,009 3.4
4 7,825 4.5 1,497 3.4 1,124 2.7 3,856 4.5 2,488 4.2
Deprived 6,046 3.5 1,262 2.9 918 2.2 4,767 5.5 3,061 5.2
65–74 Afﬂuent 7,401 4.3 2,944 6.7 2,164 5.1 3,898 4.5 2,167 3.7
2 7,399 4.3 2,954 6.7 2,391 5.7 4,764 5.5 2,823 4.8
3 7,129 4.1 2,807 6.4 2,367 5.6 5,554 6.4 3,402 5.8
4 6,612 3.8 2,762 6.3 2,193 5.2 7,014 8.1 4,363 7.4
Deprived 5,219 3.0 2,481 5.6 1,884 4.5 7,950 9.2 5,290 9.0
75–99 Afﬂuent 7,309 4.2 3,616 8.2 3,891 9.2 5,020 5.8 3,221 5.5
2 8,626 5.0 3,997 9.1 4,547 10.8 6,273 7.3 4,302 7.3
3 9,288 5.3 4,115 9.3 4,865 11.5 7,213 8.3 5,089 8.6
4 9,190 5.3 4,039 9.2 4,850 11.5 8,359 9.7 6,404 10.8
Deprived 6,655 3.8 3,013 6.8 3,622 8.6 8,023 9.3 6,404 10.8
Total 173,886 100.0 44,104 100.0 42,274 100.0 86,501 100.0 59,031 100.0
U. Nur et al. / Cancer Epidemiology 39 (2015) 641–649 643(94–98%) in the four age groups (15–44, 45–54, 55–64 and 65–74
years). For women diagnosed later in life (75–99 years), 1-year
survival was still high (85.1%) but substantially lower than that of
younger women. Survival of afﬂuent breast cancer patients
diagnosed in the 15–44 and 55–64 years age groups was similar
up to 1 year after diagnosis. However, survival of afﬂuent patients
in the 55–64 age group was the highest of all up to 10 years after
diagnosis (Fig. 2, Appendix 1–3). The ‘deprivation gap’ widened
steadily from 0.8% for women diagnosed early in life (15–44
years) to 4.8% for women diagnosed late in life (75–99 years) for
1-year survival. The gap was widest for women aged 6574 years
at diagnosis (Fig. 2); 8.3% at 5 years (Fig. 1) and 8.9% at 10 years
(Table 3).
For colon cancer, 1-year survival for all deprivation groups
combined ranged between 80.8% and 77.2% for men and between
78.6% and 83.2% in the three age groups (15–44, 45–54 and 55–64).
Survival was much lower for men (59.6%) and women (56.2%)
diagnosed aged 75–99 years. Socioeconomic inequalities in
survival were apparent for all age groups and both sexes up to
10 years after diagnosis. The deprivation gap in men was widest for
those aged 55–64 years. The deprivation gap in 1- and 5-year
survival in men ranged between 6.5% and 8.8% for those who
were 45 years or older at diagnosis, with a narrower gap for men
diagnosed early in life (15–44 years); 1.0% and 2.1% for 1- and 5-
year survival, respectively (Fig. 1). Pattern of survival for colon
cancer in women was different, with the widest deprivation gap in
the youngest age group (15–44 years), however, only 2.5% of
women were diagnosed at this age (Table 2).
One-year survival for lung cancer patients in all deprivation
groups combined ranged between 40.3% and 31.3% in men and
47.6% and 36.3% in women in the three age groups 15–44, 45–54
and 55–64 years. Survival was much lower in the oldest age group
for both men (19%) and women (20%). The ‘deprivation gap’ wasmore than 10% for 1-year survival in men and for 1- and 5-year
survival in women aged 15–44 years. However, these groups
include less than 2% of all patients, and hence a wide conﬁdence
interval is apparent. Patients diagnosed aged 75 years and older
comprise more than 40% of the lung cancer population in men and
women (Table 2). The ‘deprivation gap’ narrowed by age group and
was less than 1% for both sexes in the oldest age groups for 5- and
10-year survival in both men and women.
4. Discussion
We studied the effect of age on socioeconomic differences in
cancer survival for more than 400,000 patients diagnosed 2001–
2005 with one of three common cancers (breast, colon and lung) in
England. The applied methodology could be extended to under-
stand international age-speciﬁc socioeconomic differences, and
factors that have an impact on differences in magnitude and
pattern of cancer survival between England and other countries if it
exists. Age at diagnosis has a different inﬂuence on socioeconomic
inequalities in survival for each of these cancers. Older age was
associated with wider socioeconomic inequalities in short-term
breast cancer survival, whilst the opposite was true for lung. No
association between age at diagnosis and the deprivation gap was
apparent for colon cancer.
Survival of patients in the most deprived groups was
signiﬁcantly lower than that of the most afﬂuent groups for all
three cancers in both sexes, extending similar ﬁndings made for
patients diagnosed during 1971–1990 [1] and 1986–1999
[4]. While a ‘deprivation gap’ is common for most cancers and
age groups, the overall pattern of lower survival in the most
deprived groups differed between the ﬁve age groups.
Breast cancer is unique in that the deprivation gap is wider for
women diagnosed at older ages. The average 1-year survival was
Fig. 1. Deprivation gap (%) in 1- and 5-year survival for ﬁve age groups, patients diagnosed 2001–2005, England.
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diagnosed before the age of 65, suggesting a ‘ceiling effect’. Any
further improvements in survival would be expected to be
principally concentrated in women in the more deprived groups,
whose survival has been lower. Socioeconomic inequalities in
survival were still evident in all age groups up to 10 years after
diagnosis. Afﬂuent women beneﬁt more from screening than
deprived women, and are diagnosed at an earlier stage
[20]. Therefore, screening could be one of the possible explana-
tions of this survival inequality. The persistent long-term
inequality, wider for older age groups, may also indicate
socioeconomic disparities in the management of primary tumours
and/or recurrences in old age [21].For lung cancer, the socioeconomic differences in survival
occurred among the relatively small group of patients diagnosed at
a young age, and tended to diminish with time since diagnosis
[22]. Lung cancer is not commonly seen under the age of 45: it
typically accounts for less than 3% of all lung cancer patients under
40 years [23–25]. In our study, the difference in survival of lung
cancer patients, between rich and poor was apparent at all age
groups, but with different magnitude. The percentage of lung
cancer patients under the age of 45 was 1.1% in men and 1.6% in
women. A higher percentage of young lung cancer patients would
present with advanced stage in comparison to patients over the age
of 45, by the time they are referred to a specialist [26]. However,
survival of young patients is much better than those diagnosed at
Fig. 2. Trends in 1–10 year net survival (%) for the most deprived and the most afﬂuent groups, by cancer and sex in the three age groups (15–44, 55–64 and 75–99), England.
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lung cancer in men and 43% of lung cancer in women. In both sexes
survival in this age group was almost half that of the youngest
group. Patients diagnosed at older ages are less likely to be treated
by surgery, independently of their deprivation group [27]. The
similarly low survival of all deprivation categories suggests that
rich and poor are equally disadvantaged with respect to treatment.
It would seem that socioeconomic inequalities in treatment (and
particularly surgery) [27,28], are likely to be concentrated in
patients in the younger age group, and this is likely to explain why
the wider deprivation gaps are seen among younger lung cancer
patients.
Socioeconomic inequalities in colon cancer survival have been
well documented [1]. A general pattern of higher survival ofafﬂuent patients compared to deprived, with a wide and similar
‘deprivation gap’ among all high-risk age groups (older than
55 years) is clear, in men and women up to 10 years after diagnosis.
In our study, more than 90% of the patients were diagnosed after
the age of 55 years. Stage at diagnosis and access to optimal
treatment have a major impact on survival and may thus explain at
least part of the difference in survival between rich and poor in all
age groups [2]. We have already shown that given equal treatment
at a given stage of disease, colorectal cancer survival does not
depend on socioeconomic status [29]. Although older colon cancer
patients are less likely to receive recommended therapy [30], there
was no evidence of socioeconomic variation in stage at diagnosis
for colon cancer patients [31]. This evidence, combined with
ﬁndings from our study, suggests that older, deprived patients are
Table 3
Net survival (%) at 1, 5 and 10 years and deprivation gap (with 95% CI), by age category for patients diagnosed during 2001–2005, and followed up to 2011 in England.
Survival Age group Breast Colon Lung
Women Men Women Men Women
Deprivation gap Deprivation gap Deprivation gap Deprivation gap Deprivation gap
Net survival % 95% CI Net survival % 95% CI Net survival % 95% CI Net survival % 95% CI Net survival % 95% CI
1 year 15–44 97.8 0.8 1.4 0.2 80.8 1.0 7.5 5.5 83.2 7.2 13.5 0.9 40.3 10.7 19.5 1.9 47.6 12.3 21.3 3.2
45–54 97.9 1.5 2.0 1.1 77.2 7.5 12.1 2.9 81.6 3.1 7.5 1.3 32.3 4.6 8.5 0.8 39.0 5.8 10.2 1.5
55–64 97.2 1.7 2.2 1.2 77.2 8.5 11.2 5.7 78.6 7.5 10.6 4.4 31.3 3.9 5.9 1.8 36.3 5.7 8.4 3.0
65–74 94.3 3.8 4.6 3.0 72.7 6.7 8.9 4.4 71.5 8.5 11.0 5.9 27.2 2.5 4.0 1.0 30.0 2.7 4.7 0.7
75–99 85.1 4.8 6.1 3.5 59.6 6.9 9.2 4.6 56.2 7.6 9.8 5.5 19.4 1.0 2.3 0.3 20.4 2.3 3.8 0.8
5 year 15–44 83.4 5.2 6.7 3.7 57.9 2.1 10.2 6.0 60.9 14.8 22.9 6.7 19.5 2.1 9.1 4.9 23.7 10.0 17.8 2.2
45–54 88.2 4.6 5.7 3.6 53.6 7.1 12.7 1.4 55.8 3.0 8.7 2.7 10.3 3.1 5.7 0.5 13.3 1.6 4.7 1.4
55–64 88.3 4.5 5.5 3.5 54.2 8.8 12.2 5.4 56.9 7.2 11.0 3.4 9.0 2.1 3.4 0.8 11.7 2.9 4.7 1.0
65–74 82.3 8.3 9.8 6.8 51.9 6.5 9.3 3.7 53.2 7.7 10.7 4.7 7.2 0.9 1.9 0.1 8.9 1.5 2.8 0.2
75–99 66.4 5.1 7.4 2.8 43.0 6.6 9.7 3.6 43.1 4.6 7.4 1.8 3.9 0.9 1.7 0.2 4.3 0.8 1.7 0.1
10 year 15–44 74.5 5.7 7.7 3.7 52.7 2.0 11.2 7.1 56.2 13.9 22.7 5.1 18.0 1.5 5.3 8.3 21.3 9.5 17.8 1.1
45–54 81.7 4.8 6.3 3.3 50.0 7.9 14.2 1.5 52.0 0.9 6.9 5.2 8.0 2.5 5.1 0.1 9.7 0.0 3.1 3.1
55–64 83.0 5.1 6.7 3.5 49.7 8.6 12.8 4.3 53.2 8.7 13.2 4.2 6.6 1.6 2.9 0.2 8.5 3.6 5.5 1.6
65–74 76.9 8.9 11.5 6.3 49.2 5.2 9.4 1.1 50.0 8.2 12.3 4.1 4.9 1.2 2.4 0.0 5.9 0.9 2.4 0.6
75–99 57.8 7.4 13.0 1.8 37.8 6.1 12.4 0.3 47.1 4.5 2.1 11.0 2.6 0.2 1.3 0.9 3.0 0.0 1.2 1.2
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U. Nur et al. / Cancer Epidemiology 39 (2015) 641–649 647the most likely to be disadvantaged by lack of access to optimal
treatment.
A limitation of our study is that it does not encompass
information on stage at diagnosis, which is associated with the
socioeconomic background of breast cancer patients [32], and
may explain part of the lower survival among colon cancer
patients living in deprived areas [2]. Future studies should aim to
examine the proportion of the observed survival inequalities that
may reﬂect inequalities in stage at diagnosis or treatment, and
may be possible to conduct in the future. Information on stage at
diagnosis is rarely available in population based datasets [33]. We
therefore included all patients diagnosed with cancer in the
population and these would help to provide public health
prospective on age speciﬁc socioeconomic inequalities of cancer
survival.
In conclusion, there are substantial age-speciﬁc socioeco-
nomic inequalities in survival from cancers of the breast, lung
and colon. Reduction of socioeconomic inequalities in survival
still requires action to extend the availability of optimal
treatment and appropriate management of lung cancer patients
to all age groups, and in particular deprived breast and colon
cancer patients diagnosed after the age of 65 and 55 years
respectively, and to ensure that cancer patients, young and old,
from afﬂuent and deprived areas, seek and obtain timely access
to care.Appendix 1
Net survival with 95% conﬁdence intervals (CI) by sex and age gr
followed up to 2011 in England.
Age group Deprivation One-year survival
Breast Colon 
Female Male 
Net survival Net survival 
95% CI 95% CI 
15–44 Afﬂuent 98.0 97.6 98.4 78.8 73.5 84.0 
2 98.0 97.6 98.4 84.8 79.8 89.8 
3 98.2 97.8 98.7 79.1 73.4 84.8 
4 97.8 97.3 98.2 84.4 79.7 89.2 
Deprived 96.8 96.2 97.4 77.6 72.4 82.7 
45–54 Afﬂuent 98.5 98.2 98.8 81.4 78.1 84.7 
2 98.4 98.1 98.7 80.0 76.6 83.4 
3 98.1 97.7 98.4 75.0 71.2 78.7 
4 97.7 97.3 98.1 73.5 69.6 77.3 
Deprived 96.6 96.1 97.1 75.8 71.8 79.8 
55–64 Afﬂuent 98.0 97.7 98.3 81.2 79.3 83.0 
2 97.5 97.2 97.9 79.0 76.9 81.0 
3 97.2 96.8 97.5 76.6 74.4 78.7 
4 96.8 96.4 97.3 75.3 73.0 77.5 
Deprived 96.1 95.5 96.6 72.4 69.9 75.0 
65–74 Afﬂuent 96.0 95.4 96.5 74.6 73.0 76.2 
2 95.2 94.7 95.8 75.4 73.8 77.1 
3 94.7 94.1 95.3 73.8 72.1 75.5 
4 92.7 92.0 93.4 70.6 68.8 72.4 
Deprived 92.4 91.5 93.2 68.4 66.5 70.3 
75–99 Afﬂuent 87.6 86.6 88.5 62.3 60.6 64.1 
2 86.5 85.6 87.4 61.8 60.1 63.5 
3 84.4 83.4 85.3 59.6 57.9 61.3 
4 84.2 83.3 85.2 58.3 56.6 60.0 
Deprived 82.8 81.6 83.9 55.2 53.3 57.2 Funding
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cancer registries in England for providing the data.oup, for adults (15–99 years) diagnosed during 2001–2005, and
Lung
Female Male Female
Net survival Net survival Net survival
95% CI 95% CI 95% CI
86.2 81.9 90.6 47.2 38.5 55.9 53.1 44.6 61.5
83.1 78.0 88.3 37.5 29.2 45.9 50.0 42.2 57.9
87.5 83.1 91.9 45.7 38.8 52.7 50.9 43.5 58.3
81.2 76.1 86.4 42.4 36.0 48.8 49.3 42.5 56.2
77.5 71.8 83.1 33.8 28.5 39.0 39.8 33.8 45.7
82.3 79.2 85.5 36.7 32.8 40.6 41.8 37.7 46.0
83.7 80.5 87.0 31.9 28.6 35.2 40.6 36.8 44.3
82.0 78.6 85.3 33.0 29.8 36.1 42.8 39.2 46.4
78.2 74.3 82.1 32.6 29.9 35.4 35.9 32.8 38.9
81.1 77.3 84.9 30.2 27.9 32.5 37.2 34.4 40.0
82.0 79.9 84.1 34.3 32.3 36.3 40.9 38.3 43.6
79.5 77.3 81.7 30.8 29.0 32.6 38.3 36.0 40.6
78.8 76.5 81.1 31.8 30.2 33.5 36.2 34.1 38.3
78.0 75.5 80.4 32.4 30.9 33.9 34.0 32.1 35.9
72.8 69.9 75.7 28.9 27.6 30.2 35.1 33.4 36.8
75.4 73.6 77.3 28.2 26.8 29.7 32.3 30.3 34.2
74.2 72.4 76.0 28.1 26.8 29.4 30.3 28.6 32.0
70.8 68.9 72.7 28.3 27.1 29.5 30.8 29.2 32.4
68.5 66.5 70.5 26.3 25.3 27.4 28.7 27.3 30.1
67.9 65.7 70.1 26.2 25.2 27.1 29.4 28.1 30.6
60.6 58.9 62.2 20.7 19.6 21.9 22.4 20.9 23.9
57.3 55.8 58.9 19.2 18.2 20.3 20.2 18.9 21.4
56.4 54.8 57.9 19.3 18.3 20.2 21.2 20.1 22.4
54.3 52.8 55.8 18.9 18.0 19.8 19.7 18.7 20.8
52.5 50.7 54.3 19.4 18.5 20.3 19.6 18.6 20.6
Appendix 2
Net survival with 95% conﬁdence intervals (CI) by sex and age group, for adults (15–99 years) diagnosed during 2001–2005, and
followed up to 2011 in England.
Age group Deprivation Five-year survival
Breast Colon Lung
Female Male Female Male Female
Net survival Net survival Net survival Net survival Net survival
95% CI 95% CI 95% CI 95% CI 95% CI
15–44 Afﬂuent 85.6 84.6 86.6 57.2 50.8 63.7 67.9 61.9 73.8 19.7 12.8 26.6 28.1 20.5 35.7
2 84.6 83.5 85.8 60.6 53.7 67.4 61.4 54.7 68.2 14.9 8.8 21.0 28.0 20.9 35.0
3 83.5 82.3 84.7 57.9 50.9 64.9 66.8 60.5 73.1 21.9 16.1 27.7 27.0 20.4 33.7
4 82.0 80.8 83.3 58.7 52.2 65.3 54.9 48.4 61.5 24.2 18.6 29.8 19.2 13.8 24.6
Deprived 80.3 78.9 81.7 – – – 52.6 45.9 59.4 16.4 12.2 20.5 20.2 15.4 25.1
45–54 Afﬂuent 89.9 89.3 90.6 58.5 54.3 62.7 58.2 54.0 62.3 13.4 10.6 16.2 14.0 11.0 16.9
2 89.5 88.8 90.3 53.5 49.2 57.8 55.7 51.3 60.1 10.9 8.7 13.1 13.6 10.9 16.2
3 88.0 87.2 88.8 53.7 49.4 58.0 56.0 51.6 60.4 9.5 7.5 11.4 13.7 11.2 16.2
4 87.2 86.3 88.0 49.4 44.9 53.9 51.9 47.2 56.7 10.5 8.7 12.3 13.8 11.6 16.0
Deprived 85.0 84.0 86.0 52.2 47.4 56.9 56.7 51.8 61.6 9.1 7.6 10.5 12.1 10.2 14.0
55–64 Afﬂuent 90.0 89.3 90.6 58.0 55.6 60.4 59.5 56.8 62.3 10.7 9.4 12.0 14.5 12.6 16.4
2 89.3 88.6 90.0 56.6 54.1 59.2 58.0 55.3 60.8 9.0 7.8 10.1 12.0 10.4 13.6
3 88.1 87.4 88.9 52.8 50.1 55.4 58.0 55.2 60.8 9.1 8.0 10.1 11.9 10.5 13.4
4 87.2 86.4 88.1 53.1 50.4 55.8 56.3 53.2 59.3 9.2 8.2 10.1 10.9 9.6 12.1
Deprived 85.0 84.0 86.1 48.5 45.5 51.6 50.8 47.3 54.2 7.9 7.1 8.7 10.9 9.8 12.0
65–74 Afﬂuent 85.5 84.5 86.5 54.0 52.0 56.1 57.1 54.9 59.4 8.3 7.4 9.2 9.7 8.4 11.0
2 84.4 83.4 85.5 53.3 51.3 55.4 55.8 53.6 58.0 6.7 5.9 7.5 10.1 9.0 11.3
3 82.3 81.2 83.5 53.8 51.6 56.0 51.9 49.6 54.1 7.7 6.9 8.5 8.4 7.4 9.3
4 80.6 79.4 81.9 50.9 48.6 53.1 49.8 47.4 52.1 6.8 6.2 7.5 8.9 8.0 9.8
Deprived 76.4 75.0 77.9 46.7 44.3 49.1 50.9 48.3 53.5 6.9 6.3 7.6 8.3 7.5 9.1
75–99 Afﬂuent 66.3 64.6 68.1 44.4 42.1 46.6 44.7 42.6 46.9 4.3 3.7 5.0 4.4 3.6 5.2
2 69.2 67.4 71.0 46.2 43.9 48.6 44.5 42.4 46.6 4.4 3.8 5.1 5.1 4.3 5.9
3 67.0 65.2 68.8 42.6 40.4 44.9 43.9 41.8 46.0 3.8 3.2 4.3 4.4 3.7 5.1
4 67.3 65.4 69.2 43.8 41.4 46.1 41.5 39.4 43.5 3.6 3.1 4.1 4.0 3.4 4.6
Deprived 60.2 58.2 62.2 36.8 34.2 39.4 40.5 38.1 42.8 3.6 3.0 4.1 4.1 3.5 4.6
Appendix 3
Net survival with 95% conﬁdence intervals (CI) by sex and age group, for adults (15–99 years) diagnosed during 2001–2005, and
followed up to 2011 in England.
Age group Deprivation Ten-year survival
Breast Colon Lung
Female Male Female Male Female
Net survival Net survival Net survival Net survival Net survival
95% CI 95% CI 95% CI 95% CI 95% CI
15–44 Afﬂuent 77.2 75.8 78.7 52.9 45.9 59.9 62.4 55.8 69.0 17.2 10.5 23.8 23.7 15.4 31.9
2 75.5 74.0 77.0 53.8 46.4 61.2 56.1 48.6 63.6 12.6 6.9 18.4 28.2 21.1 35.3
3 74.8 73.2 76.5 53.6 45.8 61.4 63.2 56.5 69.9 19.9 14.3 25.5 24.1 17.3 30.9
4 72.8 71.1 74.5 52.2 44.4 60.1 50.8 43.8 57.8 23.1 17.5 28.7 14.0 7.0 21.1
Deprived 71.4 69.6 73.1 51.1 43.9 58.3 47.6 40.3 55.0 15.5 11.3 19.8 18.6 13.5 23.8
45–54 Afﬂuent 83.6 82.7 84.6 54.1 49.4 58.8 52.9 48.5 57.3 10.3 7.6 13.1 9.6 6.8 12.4
2 82.6 81.6 83.7 52.0 47.6 56.5 52.2 47.4 56.9 8.8 6.6 10.9 10.07 2 12 12.7
3 81.7 80.5 82.8 50.1 45.3 54.9 51.9 47.2 56.7 7.3 4.9 9.7 9.6 7.2 12.0
4 81.0 79.8 82.2 44.6 39.7 49.5 49.3 44.3 54.3 7.9 6.2 9.7 9.4 7.2 11.5
Deprived 78.1 76.7 79.6 48.7 43.2 54.2 53.6 48.4 58.7 7.2 5.7 8.7 9.9 7.7 12.0
55–64 Afﬂuent 84.9 83.9 85.9 53.8 50.9 56.7 55.9 52.7 59.0 8.2 6.8 9.6 10.7 8.6 12.8
2 84.4 83.4 85.5 51.4 48.2 54.5 54.9 51.8 58.0 6.3 5.1 7.4 10.0 8.5 11.6
3 83.0 81.8 84.1 48.5 45.3 51.7 55.2 52.0 58.5 6.9 5.8 8.0 8.6 7.1 10.2
4 81.2 79.9 82.6 48.6 45.0 52.1 53.0 49.5 56.6 6.8 5.8 7.8 7.5 6.2 8.8
Deprived 79.9 78.3 81.5 44.5 40.6 48.4 44.3 40.1 48.5 5.8 5.0 6.7 7.3 6.1 8.5
65–74 Afﬂuent 80.2 78.5 81.8 50.5 47.6 53.4 54.2 51.2 57.1 5.7 4.6 6.8 5.8 4.3 7.3
2 79.4 77.5 81.2 49.9 46.8 52.9 53.4 50.4 56.5 4.8 4.0 5.7 6.8 5.4 8.1
3 77.0 75.0 79.0 53.3 50.1 56.5 46.6 43.4 49.9 5.6 4.7 6.5 6.1 5.0 7.2
4 76.5 74.4 78.6 47.6 44.2 51.1 48.6 45.4 51.7 4.2 3.4 5.0 5.9 4.9 7.0
Deprived 69.1 66.6 71.7 44.1 40.3 47.8 46.7 43.0 50.4 4.5 3.7 5.4 5.3 4.4 6.3
U. Nur et al. / Cancer Epidemiology 39 (2015) 641–649648
Appendix 3 (Continued )
Age group Deprivation Ten-year survival
Breast Colon Lung
Female Male Female Male Female
Net survival Net survival Net survival Net survival Net survival
95% CI 95% CI 95% CI 95% CI 95% CI
75–99 Afﬂuent 55.3 51.0 59.6 37.4 32.4 42.4 41.6 36.9 46.3 2.4 1.6 3.3 2.5 1.5 3.6
2 63.2 58.3 68.1 39.1 33.9 44.4 49.1 42.9 55.4 3.1 2.0 4.1 3.8 2.6 5.0
3 58.1 52.6 63.6 40.8 36.0 45.6 47.1 41.2 53.0 2.6 1.7 3.5 3.3 2.3 4.3
4 60.4 54.6 66.2 38.5 32.7 44.3 50.1 44.6 55.6 2.3 1.4 3.1 2.4 1.5 3.3
Deprived 48.5 44.3 52.7 30.8 26.0 35.6 45.5 40.1 50.9 2.5 1.7 3.3 3.1 2.3 3.9
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